The Big Heart Disease Lie

Latest Treatment for Heart Disease

Get Instant Access

1. Myerburg R, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-1197.

2. DiMarco JP, Haines DE. Sudden cardiac death. Curr Probl Cardiol 1990:187-232.

3. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of anti-arrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.

4. Stevenson WG, Friedman PL. Catheter Ablation of Ventricular Tachycardia. In: Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside, 3rd ed. WB Saunders Co., Philadelphia, PA, 2000, pp. 1049-1056.

5. Mirowski M. The Automatic implantable cardioverter-defibrillator: an overview. J Am Coll Cardio 1985;6:461-466.

6. Gregoratos G, Cheitlin M, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 1998;31:1175-1209.

7. Karagueuzian HS, Mandel WJ. Electrophysiologic Mechanisms of Ischemic Ventricular Arrhythmias: Experimental and Clinical Correlations. In: Mandel WJ. Cardiac Arrhythmias: Their Mechanisms, Diagnosis, and Management. J.B. Lippincott Company, Philadelphia, PA, 1995, pp. 563-603.

8. The Multicenter Postinfarction Research Group. Risk Stratification and Survival After Myocardial Infarction. N Engl J Med 1983;309:331-336.

9. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-258.

10. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction. N Engl J Med 1982;306:1065-1070.

11. Mukharji J, Rude R, Poole W, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31-36.

12. Richards D, Byth K, Ross D, et al. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction. Circulation 1991;83:756-763.

13. Pedretti R, Etro M, Laporta A, et al. Prediction of late arrhythmic events after acute myocardial infarction from combined use of non-invasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993;71:1131-1141.

14. Denniss AR, Richards DA, Cody DV, et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986;74:731-745.

15. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987;9:531-538.

16. Moss A, Hall W, Cannom D, et al., for the Multicenter Automatic Defibrillator Implantation Trial (MADIT) Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.

17. The B-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-1714.

18. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.

19. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.

20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

21. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.

22. Pfeffer M, Braunwald E, Moye L, et al. for the Survival and Ventricular Enlargement Trial (SAVE) Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.

22a.Kober L, Torp-Pederson C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676.

22b.Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604.

23. Echt D, Liebson P, Mitchell B, et al., for the Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.

24. Teo K, Yusuf S, Furber C. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trial. JAMA 1993;270:1589-1595.

25. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.

26. Singh S, Fletcher R, Fisher S, et al. for the Survival Trail of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT) Investigators. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.

27. Julian D, Camm A, Frangin G, et al. for the European Myocardial Infarct Amiodarone Trial (EMIAT) Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.

28. Cairns J, Connolly S, Roberts R, et al. for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) Investigators. Lancet 1997;349:675-682.

28a. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350:1417-1423.

29. Waldo A, Camm A, deRuyter H, et al. For the Survival With Oral d-Sotalol (SWORD) Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.

30. Bigger J, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997;337:1569-1575.

30a.Bigger JT Jr, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999;99:1416-1421.

31. Buxton A, Fisher J, Josephson M, et al. for the Multicenter Unsustained Tachycardia Trial (MUSTT) Investigators. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993;36:215-226.

32. Buxton AE, Lee KL, Fisher JD, et al. for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890.

32a.Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000 Jun 29;342(26):1937-1945.

33. Klein H, Auricchio A, Reek Sven, et al. New Primary Prevention trial of Sudden Cardiac Death in Patients with Left Ventricular Dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999;83:91D-97D.

34. Gilman J, Jalal S, Naccarelli G. Predicting and preventing sudden death from cardiac causes. Circulation 1994;90:1083-1092.

35. Domanski M, Zipes D, Schron E. Treatment of sudden cardiac death. Circulation 1997;95:2694-2699.

36. Cannom D, Prystowski E. Management of ventricular arrhythmias. JAMA 1999;281:172-179.

37. Doval H, Nul D, Grancelli H, et al., for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Investigators. Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.

37a.Kadish A, Quigg R, Schaechter A, Anderson KP, Estes M, Levine J. Defibrillators in nonischemic cardiomyopathy treatment evaluation. PACE 2000;23:338-343.

38. The CASS Investigators. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery survival data. Circulation 1983;68:939-950.

39. Holmes DR, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the coronary artery surgery study. Circulation 1986;73:1254-1263.

40. The CASCADE Investigators. Randomized Antiarrhythmic Drug Therapy in Survivors of Cardiac Arrest (the CASCADE Study). Am J Cardiol 1993;72:280-287.

41. Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997;30:487-495.

42. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-sotalol implantable cardioverter-defibrillator study group. N Engl J Med 1999;340(24):1855-1862.

43. Siebels J, Cappato R, Ruppel R, et al. for the Cardiac Arrest Study Hamburg (CASH) Investigators. Preliminary Results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993;72:109F-113F.

43a.Huck K-H, Cappato R, Siebels J, Ruppel R, for the CASH investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-754.

44. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000 Mar 21; 101(11):1297-1302.

45. Fontaine G, Guiraudon G, Frank R, et al. Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery. In: Kulbertus HE, ed. Reentrant Arrhythmias. MTP Publishers, Lancaster, 1977, pp. 334-350.

46. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia. In: Podrid PJ, Kowey PR: Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management. Williams & Wilkins, Baltimore, MD, 1995, pp. 1121-1130.

46a.Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol 1998;32:724-728.

47. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hyper-trophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J 1989;61:178-181.

48. Borggrefe M, Schwammenthal E, Block M et al. Pre- and Postoperative Electrophysiological Findings in Survivors of Cardiac Arrest and Hypertrophic Obstructive Cardiomyopathy Undergoing Myomectomy (abstract). Circulation 1993;88 (Suppl):1120.

49. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-416.

49a.Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000 Feb 10;342(6):365-373.

50. Valantine H, McKenna WJ, Nihoyannopoulos P, et al. Sarcoidosis, apattern of clinical and morphological presentation. Br Heart J 1987;57:256-263.

51. Winters SL, Cohen M, GreenbergS, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy, and an implantable antitachycardia device. J Am Coll Cardiol 1991;18: 937.

52. Sosa E, Scanavacca M, D'Avila A, et al. Endocardial and epicardial ablation guided by non-surgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol 1998;9(3):229-239.

53. Belhassen B, Rotmensch HH, Laniago S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J 1981;46:679-682.

54. Zipes DP, Foster PR, Troup PJ. Atrial induction of ventricular tachycardia: reentry versus triggered automaticity. Am J Cardiol 1978;44:1-8.

55. Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a purkinje potential. Circulation 1993;88:2607-2617.

56. Gallarvardin Ll. Extrasystolie Ventriculaire a Paroxysmes Tachycardiques Prolonges. Arch Mal Coeur 1922;15:298.

57. Jackman W, Friday K, Anderson J, Aliot E, Clark M, Lazzara R. The Long QT Syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.

58. Napolitano C, Priori S, Schwartz P. Torsade de pointes: mechanisms and management. Drugs 1994;47:51-65.

59. Kay G, Plumb V, Arciniegas J, Henthorn R, Waldo A. Torsade de pointes: the long-short initiation sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983;2:806-817.

60. Keren A, Tzivoni D, Gavish D, Levi J, Gottlieb S, Benhorin J, et al. Etiology, warning signs and therapy of torsade de pointes. Circulation 1981;64:1167-1174.

61. Saxon L, Wiener I, Natterson P, Laks H, Drinkwater D, Stevenson W. Monomorphic versus polymorphic ventricular tachycardia after coronary artery bypass grafting. Am J Cardiol 1995;75:403-405.

62. Wolfe C, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991;84:1543-1551.

63. Carter J, Childers R. Torsade de pointes complicating acute myocardial infarction. the importance of autonomic dysfunction as assessed by heart rate variability. Clin Cardiol 1992;15:769-772.

64. Eisenberg SJ, Scheinman MM, Dullet NK, et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. Am J Cardiol 1995;75:687-692.

65. Dessertenne F. La Tachycardie Ventriculaire a Deux Foyers Opposes Variable. Arch Mal Coeur 1966;59:263-272.

66. Dhurandhar RW, Macmillan RL, Brown KW. Primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1990;66:1208-1211.

66a.Volpi A, Cavalli A, Santoro L, et al. Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction—results of the gruppo italiano per lo studio della sopravvivenza nell'infarcto miocardico (GISSI-2) database. Am J Cardiol 1998;82:265-271.

66b.Kelly P, Ruskin J, Vlahakes GJ, Buckley MJ, Freeman CS, Garan H. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990;15:267-272.

66c. Natale A, Sra J, Axtell K, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 1994;5:988-994.

66d.Marcus FI. Idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997;8:1075-1083.

66e. Consensus statement. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Circulation 1997;95:265-272.

66f. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10:1301-1312.

66g.Ruskin JN. Idiopathic ventricular fibrillation: is there a role for electrophysiologic-guided antiarrhythmic drug therapy? J Cardiovasc Electrophysiol 1999;10:1313-1315.

67. Antzelevitch C. The Brugada Syndrome. J Cardiovasc Electrophysiol 1998;9:513-516.

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment